董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Aaron Royston | 男 | Director | 39 | 未披露 | 未持股 | 2023-09-01 |
| Mary Tagliaferri | 女 | Director | 56 | 30.31万美元 | 未持股 | 2023-09-01 |
| Christy Oliger | 女 | Director | 53 | 未披露 | 未持股 | 2023-09-01 |
| Richard Heyman | 男 | Chairman of the Board and Director | 66 | 236.13万美元 | 未持股 | 2023-09-01 |
| Aaron Kantoff | 男 | Director | 38 | 27.04万美元 | 未持股 | 2023-09-01 |
| Maha Katabi | 女 | Director | 50 | 未披露 | 未持股 | 2023-09-01 |
| Yi Larson | 女 | Director | 43 | 27.04万美元 | 未持股 | 2023-09-01 |
| Christy Oliger | 女 | Director | 53 | 未披露 | 未持股 | 2023-09-01 |
| Mary Tagliaferri | 女 | Director | 57 | 未披露 | 未持股 | 2023-09-01 |
| Angie You | 女 | Director | 50 | 84.12万美元 | 未持股 | 2023-09-01 |
| Ken Song | 男 | President, Chief Executive Officer and Director | 48 | 572.49万美元 | 未持股 | 2023-09-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ken Song | 男 | President, Chief Executive Officer and Director | 48 | 572.49万美元 | 未持股 | 2023-09-01 |
| Arvind Kush | 男 | Chief Financial Officer | 40 | 194.12万美元 | 未持股 | 2023-09-01 |
| Susan Moran | 女 | Chief Medical Officer | 54 | 190.84万美元 | 未持股 | 2023-09-01 |
董事简历
中英对照 | 中文 | 英文- Aaron Royston
-
Aaron Royston自2017年9月以来一直担任我们的董事会成员。Royston博士是Venbio Partners（一家生命科学投资公司）的管理合伙人，自2015年11月起在Venbio Partners任职。加入Venbio Partners之前，Royston从2014年7月到2015年11月在Vivo Capital（一家全球生命科学投资公司）任职。此前，他曾任职Bain&Company（从2013年7月到2014年7月），在那里他曾为生物技术公司提供广泛的战略和运营问题的建议。职业生涯早期，Royston博士在西奈山医学中心（Mount Sinai Medical Center）协调临床研究，在那里他的研究已经发表并在多个医学期刊和会议上发表。2011年，Royston博士因其在技术和创新方面的工作而被奥巴马政府认可为变革的拥护者。Royston博士此前曾在Akero Therapeutics（一家上市生物技术公司）和Menlo Therapeutics，Inc.（一家上市生物技术公司）的董事会任职，目前在几家私人公司的董事会任职。Royston博士在杜克大学（Duke University）获得生物科学学士学位，在宾夕法尼亚大学（University of Pennsylvania）获得医学博士学位和工商管理硕士学位。
Aaron Royston has served as managing partner at venBio Partners, a life sciences investment firm, since April 2020 and has been with venBio Partners since 2015. Prior to joining venBio Partners, Dr. Royston served as a Senior Associate at Vivo Capital, a global life sciences investment firm from July 2014 to November 2015. Previously, Dr. Royston served as a consultant at Bain & Company, Inc. from July 2013 to July 2014 where he advised biotechnology companies on a broad range of strategic and operational issues. Earlier in his career, Dr. Royston coordinated clinical research at Mount Sinai Medical Center, where his research has been published and presented in multiple medical journals and conferences. Dr. Royston previously served on the boards of directors of Rayze Bio, from August 2020 until November 2023, Ventyx Biosciences, Inc., a publicly traded biotechnology company, from March 2021 until January 2023, Akero Therapeutics, Inc., a publicly traded biotechnology company, from June 2018 until August 2019, and VYNE Therapeutics Inc. (formerly Menlo Therapeutics Inc.), a publicly traded biotechnology company, from June 2017 until August 2019. Dr. Royston currently serves on the board of directors of several private companies. Dr. Royston received a B.S. in biological sciences from Duke University, and an M.D. and M.B.A. from the University of Pennsylvania. - Aaron Royston自2017年9月以来一直担任我们的董事会成员。Royston博士是Venbio Partners（一家生命科学投资公司）的管理合伙人，自2015年11月起在Venbio Partners任职。加入Venbio Partners之前，Royston从2014年7月到2015年11月在Vivo Capital（一家全球生命科学投资公司）任职。此前，他曾任职Bain&Company（从2013年7月到2014年7月），在那里他曾为生物技术公司提供广泛的战略和运营问题的建议。职业生涯早期，Royston博士在西奈山医学中心（Mount Sinai Medical Center）协调临床研究，在那里他的研究已经发表并在多个医学期刊和会议上发表。2011年，Royston博士因其在技术和创新方面的工作而被奥巴马政府认可为变革的拥护者。Royston博士此前曾在Akero Therapeutics（一家上市生物技术公司）和Menlo Therapeutics，Inc.（一家上市生物技术公司）的董事会任职，目前在几家私人公司的董事会任职。Royston博士在杜克大学（Duke University）获得生物科学学士学位，在宾夕法尼亚大学（University of Pennsylvania）获得医学博士学位和工商管理硕士学位。
- Aaron Royston has served as managing partner at venBio Partners, a life sciences investment firm, since April 2020 and has been with venBio Partners since 2015. Prior to joining venBio Partners, Dr. Royston served as a Senior Associate at Vivo Capital, a global life sciences investment firm from July 2014 to November 2015. Previously, Dr. Royston served as a consultant at Bain & Company, Inc. from July 2013 to July 2014 where he advised biotechnology companies on a broad range of strategic and operational issues. Earlier in his career, Dr. Royston coordinated clinical research at Mount Sinai Medical Center, where his research has been published and presented in multiple medical journals and conferences. Dr. Royston previously served on the boards of directors of Rayze Bio, from August 2020 until November 2023, Ventyx Biosciences, Inc., a publicly traded biotechnology company, from March 2021 until January 2023, Akero Therapeutics, Inc., a publicly traded biotechnology company, from June 2018 until August 2019, and VYNE Therapeutics Inc. (formerly Menlo Therapeutics Inc.), a publicly traded biotechnology company, from June 2017 until August 2019. Dr. Royston currently serves on the board of directors of several private companies. Dr. Royston received a B.S. in biological sciences from Duke University, and an M.D. and M.B.A. from the University of Pennsylvania.
- Mary Tagliaferri
-
Mary Tagliaferri自2020年11月17日起担任公司董事。Tagliaferri博士目前是公司审计委员会的成员。Tagliaferri博士自2020年3月起一直担任纳斯达克上市公司Nektar Therapeutics的高级副总裁兼执行临床研究员，此前曾于2017年11月至2020年3月高级副总裁，担任首席医疗官2017年4月至2017年10月的临床开发和2015年1月至2017年3月的临床开发Vice President。Tagliaferri博士从2014年3月到2014年12月担任InterMune的顾问。Tagliaferri博士从2012年10月到2014年4月担任Kanglaite，Inc.的首席医疗官。Tagliaferri博士是曾在纳斯达克上市的Bionovo，Inc.的联合创始人，该公司于2012年10月26日向美国加州北区破产法院提交了第7章（Chapter7）请愿书，目前已不再活跃，并担任其首席医疗官和首席监管官，秘书兼财务主管和董事会成员（从2002年2月到2012年6月）和总裁（从2007年5月到2012年6月）。Tagliaferri博士于1988年在康奈尔大学（Cornell University）获得农业经济与商业管理理学学士学位，1996年在布林莫尔学院（Bryn Mawr College）获得理学士学位，1996年在旧金山美国中医学院（American College of Traditional China Medicine）获得东方医学理学硕士学位，California于1995年获得加州大学旧金山分校医学学位。Tagliaferri博士于2003年在加州奥克兰Alameda County Medical Center完成内科住院医师学位，并于1999年在加州大学旧金山分校（University of California，San Francisco）获得转化科学研究金。她为大约70种出版物撰稿。
Mary Tagliaferri,has been a director of the Company since November 2020 and served as Chair of the Board from January 2022 to October 26, 2023. Dr. Tagliaferri is currently chair of the Company's Nominating & Governance Committee and a member of both the Company's Audit Committee and Compensation Committee. Dr. Tagliaferri has been serving on the board of directors of RayzeBio, Inc., a biotechnology company, since October 2021. Dr. Tagliaferri has been serving as Senior Vice President and Executive Clinical Fellow for Nektar Therapeutics, a Nasdaq-listed company, since March 2020 and previously served as Chief Medical Officer from November 2017 to March 2020, Senior Vice President, Clinical Development from April 2017 to October 2017 and Vice President of Clinical Development from January 2015 to March 2017. Dr. Tagliaferri served as Consultant for InterMune from March 2014 to December 2014. Dr. Tagliaferri served as Chief Medical Officer of Kanglaite, Inc. from October 2012 to April 2014. Dr. Tagliaferri was the co-founder of Bionovo, Inc. and served as its Chief Medical Officer, Chief Regulatory Officer, Secretary and Treasurer and a member of the Board of Directors from February 2002 to June 2012 and President from May 2007 to June 2012. Dr. Tagliaferri received her Bachelor of Science Degree in Agricultural Economics and Business Management from Cornell University in 1988, Post Baccalaureate Degree in Science from Bryn Mawr College in 1996, Master of Science Degree, Oriental Medicine from the American College of Traditional Chinese Medicine, San Francisco, California in 1995 and Medical Degree from the University of California, San Francisco in 2002. Dr. Tagliaferri completed her residency in internal medicine at Alameda County Medical Center, Oakland, California, in 2003 and a research fellowship in translational science at the University of California, San Francisco in 1999. She has contributed to approximately 70 publications. - Mary Tagliaferri自2020年11月17日起担任公司董事。Tagliaferri博士目前是公司审计委员会的成员。Tagliaferri博士自2020年3月起一直担任纳斯达克上市公司Nektar Therapeutics的高级副总裁兼执行临床研究员，此前曾于2017年11月至2020年3月高级副总裁，担任首席医疗官2017年4月至2017年10月的临床开发和2015年1月至2017年3月的临床开发Vice President。Tagliaferri博士从2014年3月到2014年12月担任InterMune的顾问。Tagliaferri博士从2012年10月到2014年4月担任Kanglaite，Inc.的首席医疗官。Tagliaferri博士是曾在纳斯达克上市的Bionovo，Inc.的联合创始人，该公司于2012年10月26日向美国加州北区破产法院提交了第7章（Chapter7）请愿书，目前已不再活跃，并担任其首席医疗官和首席监管官，秘书兼财务主管和董事会成员（从2002年2月到2012年6月）和总裁（从2007年5月到2012年6月）。Tagliaferri博士于1988年在康奈尔大学（Cornell University）获得农业经济与商业管理理学学士学位，1996年在布林莫尔学院（Bryn Mawr College）获得理学士学位，1996年在旧金山美国中医学院（American College of Traditional China Medicine）获得东方医学理学硕士学位，California于1995年获得加州大学旧金山分校医学学位。Tagliaferri博士于2003年在加州奥克兰Alameda County Medical Center完成内科住院医师学位，并于1999年在加州大学旧金山分校（University of California，San Francisco）获得转化科学研究金。她为大约70种出版物撰稿。
- Mary Tagliaferri,has been a director of the Company since November 2020 and served as Chair of the Board from January 2022 to October 26, 2023. Dr. Tagliaferri is currently chair of the Company's Nominating & Governance Committee and a member of both the Company's Audit Committee and Compensation Committee. Dr. Tagliaferri has been serving on the board of directors of RayzeBio, Inc., a biotechnology company, since October 2021. Dr. Tagliaferri has been serving as Senior Vice President and Executive Clinical Fellow for Nektar Therapeutics, a Nasdaq-listed company, since March 2020 and previously served as Chief Medical Officer from November 2017 to March 2020, Senior Vice President, Clinical Development from April 2017 to October 2017 and Vice President of Clinical Development from January 2015 to March 2017. Dr. Tagliaferri served as Consultant for InterMune from March 2014 to December 2014. Dr. Tagliaferri served as Chief Medical Officer of Kanglaite, Inc. from October 2012 to April 2014. Dr. Tagliaferri was the co-founder of Bionovo, Inc. and served as its Chief Medical Officer, Chief Regulatory Officer, Secretary and Treasurer and a member of the Board of Directors from February 2002 to June 2012 and President from May 2007 to June 2012. Dr. Tagliaferri received her Bachelor of Science Degree in Agricultural Economics and Business Management from Cornell University in 1988, Post Baccalaureate Degree in Science from Bryn Mawr College in 1996, Master of Science Degree, Oriental Medicine from the American College of Traditional Chinese Medicine, San Francisco, California in 1995 and Medical Degree from the University of California, San Francisco in 2002. Dr. Tagliaferri completed her residency in internal medicine at Alameda County Medical Center, Oakland, California, in 2003 and a research fellowship in translational science at the University of California, San Francisco in 1999. She has contributed to approximately 70 publications.
- Christy Oliger
-
Christy Oliger，自2021年起担任Replimune Group, Inc.董事会成员。她分别自2020年8月、2021年6月和2023年3月起担任制药公司Karyopharm Therapeutics Inc.、生物制药公司Reata制药公司和临床阶段免疫肿瘤公司LAVA Therapeutics的董事会成员。她曾担任Sierra Oncology, Inc.董事会成员，该公司是一家处于后期阶段的生物制药公司，从2021年6月至2022年6月被GSK收购。在此之前，奥利格女士是生物制药公司基因泰克肿瘤业务部门的高级副总裁，负责美国的所有商业活动。从2000年到2020年，奥利格在基因泰克工作了20年，担任过多个领导职务，包括IMPACT业务部高级副总裁、医药产品组合管理副总裁、产品组合规划副总裁以及血液学营销和销售副总裁。在加入基因泰克之前，奥利格女士曾在Schering-Plough担任管理职务。奥利格拥有加州大学圣巴巴拉分校的经济学学士学位。
Christy Oliger,serves on the board of directors of Karyopharm Therapeutics Inc., a Nasdaq-listed pharmaceutical company, LAVA Therapeutics, a Nasdaq-listed clinical-stage immuno-oncology company, Vera Therapeutics, Inc., a Nasdaq-listed biotechnology company, and Nuvalent, Inc., a Nasdaq-listed biopharmaceutical company, since August 2020, March 2023, April 2024, and June 2025, respectively. Previously, Ms. Oliger served as a member of the board of directors of Sierra Oncology, Inc., a late stage biopharmaceutical company from June 2021 until June 2022 when the company was acquired by GSK, Reata Pharmaceuticals, Inc. from April 2021 until June 2023 when the company was acquired by Biogen, and Rayze from September 2023 until April 2024 when the company was acquired by BMS. Ms. Oliger was previously Senior Vice President of the Oncology Business Unit at Genentech, Inc., a biopharmaceutical company, responsible for all commercial activities in the U.S. Ms. Oliger spent two decades with Genentech from 2000 to 2020, holding a number of leadership roles including Senior Vice President, IMPACT Business Unit; Vice President, Pharma Portfolio Management; Vice President, Portfolio Planning and Vice President, Hematology Marketing and Sales. Prior to Genentech, Ms. Oliger held management positions at Schering-Plough. Ms. Oliger holds a B.A. in economics from the University of California at Santa Barbara. - Christy Oliger，自2021年起担任Replimune Group, Inc.董事会成员。她分别自2020年8月、2021年6月和2023年3月起担任制药公司Karyopharm Therapeutics Inc.、生物制药公司Reata制药公司和临床阶段免疫肿瘤公司LAVA Therapeutics的董事会成员。她曾担任Sierra Oncology, Inc.董事会成员，该公司是一家处于后期阶段的生物制药公司，从2021年6月至2022年6月被GSK收购。在此之前，奥利格女士是生物制药公司基因泰克肿瘤业务部门的高级副总裁，负责美国的所有商业活动。从2000年到2020年，奥利格在基因泰克工作了20年，担任过多个领导职务，包括IMPACT业务部高级副总裁、医药产品组合管理副总裁、产品组合规划副总裁以及血液学营销和销售副总裁。在加入基因泰克之前，奥利格女士曾在Schering-Plough担任管理职务。奥利格拥有加州大学圣巴巴拉分校的经济学学士学位。
- Christy Oliger,serves on the board of directors of Karyopharm Therapeutics Inc., a Nasdaq-listed pharmaceutical company, LAVA Therapeutics, a Nasdaq-listed clinical-stage immuno-oncology company, Vera Therapeutics, Inc., a Nasdaq-listed biotechnology company, and Nuvalent, Inc., a Nasdaq-listed biopharmaceutical company, since August 2020, March 2023, April 2024, and June 2025, respectively. Previously, Ms. Oliger served as a member of the board of directors of Sierra Oncology, Inc., a late stage biopharmaceutical company from June 2021 until June 2022 when the company was acquired by GSK, Reata Pharmaceuticals, Inc. from April 2021 until June 2023 when the company was acquired by Biogen, and Rayze from September 2023 until April 2024 when the company was acquired by BMS. Ms. Oliger was previously Senior Vice President of the Oncology Business Unit at Genentech, Inc., a biopharmaceutical company, responsible for all commercial activities in the U.S. Ms. Oliger spent two decades with Genentech from 2000 to 2020, holding a number of leadership roles including Senior Vice President, IMPACT Business Unit; Vice President, Pharma Portfolio Management; Vice President, Portfolio Planning and Vice President, Hematology Marketing and Sales. Prior to Genentech, Ms. Oliger held management positions at Schering-Plough. Ms. Oliger holds a B.A. in economics from the University of California at Santa Barbara.
- Richard Heyman
-
Richard Heyman，自2022年12月起担任Rayzebio，Inc.董事会成员和Rayzebio，Inc.董事会主席。Heyman博士是ORIC制药公司、Enliven治疗公司和PMV制药公司的董事会成员。Heyman博士是Metacrine公司的联合创始人，2015年6月至2023年3月担任该公司董事会主席，2015年10月至2016年6月担任该公司临时首席执行官。Heyman博士曾于2015年11月至2022年8月担任生物技术公司Gritstone Oncology的董事会成员，并于2016年5月至2022年6月担任生物技术公司Yumanity的董事会成员。从2013年8月至2015年4月，海曼博士担任私营生物技术公司Seragon Pharmaceuticals，Inc.的首席执行官，该公司于2014年8月被基因泰克收购。在加入Seragon之前，Heyman博士是Aragon Pharmaceuticals，Inc.的联合创始人和首席执行官，直到2013年8月被强生收购。他是索尔克生物研究所董事会副主席，AACR董事会基金会副主席，加州大学圣迭戈摩尔斯癌症中心访客委员会副主席。Heyman博士在明尼苏达大学获得药理学博士学位，在康涅狄格大学获得化学学士学位。
Richard Heyman,has served as a member of Rayzebio, Inc. board of directors and as Chairman of Rayzebio, Inc. board of directors since December 2022. Dr. Heyman serves as a member of the boards of directors of ORIC Pharmaceuticals, Inc., Enliven Therapeutics, Inc. and PMV Pharmaceuticals, Inc. Dr. Heyman was the co-founder of Metacrine, Inc. and served as the Chairman of its board of directors from June 2015 to March 2023 and was a co-founder of ORIC Pharmaceuticals, Inc. and served as its interim chief executive officer from October 2015 until June 2016. Dr. Heyman previously served as a member of the board of directors of Gritstone Oncology, a biotechnology company, from November 2015 to August 2022 and Yumanity, a biotechnology company, from May 2016 to June 2022. From August 2013 until April 2015, Dr. Heyman served as the chief executive officer of Seragon Pharmaceuticals, Inc., a private biotechnology company which was acquired by Genentech in August 2014. Prior to joining Seragon, Dr. Heyman co-founded and served as the chief executive officer of Aragon Pharmaceuticals, Inc. until it was acquired by Johnson & Johnson in August 2013. He is vice chairman of the Board of Trustees at the Salk Institute for Biological Studies, on the Board Foundation for the AACR and on the Board of Visitors at the University of California at San Diego Moores Cancer Center. Dr. Heyman received a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut. - Richard Heyman，自2022年12月起担任Rayzebio，Inc.董事会成员和Rayzebio，Inc.董事会主席。Heyman博士是ORIC制药公司、Enliven治疗公司和PMV制药公司的董事会成员。Heyman博士是Metacrine公司的联合创始人，2015年6月至2023年3月担任该公司董事会主席，2015年10月至2016年6月担任该公司临时首席执行官。Heyman博士曾于2015年11月至2022年8月担任生物技术公司Gritstone Oncology的董事会成员，并于2016年5月至2022年6月担任生物技术公司Yumanity的董事会成员。从2013年8月至2015年4月，海曼博士担任私营生物技术公司Seragon Pharmaceuticals，Inc.的首席执行官，该公司于2014年8月被基因泰克收购。在加入Seragon之前，Heyman博士是Aragon Pharmaceuticals，Inc.的联合创始人和首席执行官，直到2013年8月被强生收购。他是索尔克生物研究所董事会副主席，AACR董事会基金会副主席，加州大学圣迭戈摩尔斯癌症中心访客委员会副主席。Heyman博士在明尼苏达大学获得药理学博士学位，在康涅狄格大学获得化学学士学位。
- Richard Heyman,has served as a member of Rayzebio, Inc. board of directors and as Chairman of Rayzebio, Inc. board of directors since December 2022. Dr. Heyman serves as a member of the boards of directors of ORIC Pharmaceuticals, Inc., Enliven Therapeutics, Inc. and PMV Pharmaceuticals, Inc. Dr. Heyman was the co-founder of Metacrine, Inc. and served as the Chairman of its board of directors from June 2015 to March 2023 and was a co-founder of ORIC Pharmaceuticals, Inc. and served as its interim chief executive officer from October 2015 until June 2016. Dr. Heyman previously served as a member of the board of directors of Gritstone Oncology, a biotechnology company, from November 2015 to August 2022 and Yumanity, a biotechnology company, from May 2016 to June 2022. From August 2013 until April 2015, Dr. Heyman served as the chief executive officer of Seragon Pharmaceuticals, Inc., a private biotechnology company which was acquired by Genentech in August 2014. Prior to joining Seragon, Dr. Heyman co-founded and served as the chief executive officer of Aragon Pharmaceuticals, Inc. until it was acquired by Johnson & Johnson in August 2013. He is vice chairman of the Board of Trustees at the Salk Institute for Biological Studies, on the Board Foundation for the AACR and on the Board of Visitors at the University of California at San Diego Moores Cancer Center. Dr. Heyman received a Ph.D. in pharmacology from the University of Minnesota and a B.S. in chemistry from the University of Connecticut.
- Aaron Kantoff
-
Aaron Kantoff于2020年2月至2023年9月担任Rayzebio，Inc.董事会成员，并与他人共同创立了RayzeBio，Inc.，目前是Petrichor附属公司Scion Life Sciences的联合创始人和管理合伙人。从2020年5月至2021年9月，Kantoff先生担任Medicxi的风险合伙人，这是一家专注于生命科学领域的投资公司，他在2021年1月至2022年7月期间担任Centessa制药公司的董事会成员。从2011年8月到2019年4月，坎托夫在生物技术风险投资公司Apple Tree Partners担任合伙人。在ATP任职期间，Kantoff先生担任Syntimmune，Inc.（被Alexion收购）、Corvidia Therapeutics，Inc.（被诺和诺德收购）、Akero Therapeutics, Inc.以及其他私有和上市生物技术公司的董事会成员。在加入ATP之前，坎托夫曾在私人股本和投资银行部门任职。Kantoff先生目前是Tourmaline Bio的董事会成员，这是一家专注于自身免疫性疾病的私营生物技术公司。Kantoff先生在纽约大学Leonard N. Stern商学院获得金融和国际商务学士学位。
Aaron Kantoff has served on Board since March 2024. Since January 2022, Mr. Kantoff is co founder and managing partner of Scion Life Sciences Management, LLC, which is affiliated with Petrichor Healthcare Capital Management LP. Most recently, beten April 2022 to November 2025, he has served on the board of directors of Tmaline Bio, Inc. (Nasdaq: TRML), a biotechnology company foced on autoimmune diseases. Mr. Kantoff was a co founder and board director of RayzeBio, Inc. (Nasdaq: RYZB) from April 2020 until January 2024. Previoly, he was a venture partner at Medicxi Ventures (UK) LLP ("Medicxi"), an investment firm foced on the life sciences sector. During his time as venture partner at Medicxi, he served on the board of directors of Centessa Pharmaceuticals plc (Nasdaq: CNTA) from November 2020 to July 2022. From August 2011 until April 2019, Mr. Kantoff served as a partner at Apple Tree Partners ("ATP"), a biotechnology venture capital firm. During his time at ATP, Mr. Kantoff was a board member of Syntimmune, Inc. (acquired by Alexion Pharmaceuticals, Inc. (formerly Nasdaq: PALXN), which was subsequently subject to a tender offer by a third party), Corvidia Therapeutics, Inc. (acquired by Novo Nordisk A/S (NYSE: NVO)), Akero Therapeutics, Inc. (previoly Nasdaq: AKRO), as ll as other privately held and publicly traded biotechnology companies. Prior to joining ATP, Mr. Kantoff held roles in private equity and investment banking. Mr. Kantoff received a B.S. in finance and international biness from the New York University Leonard N. Stern School of Biness. - Aaron Kantoff于2020年2月至2023年9月担任Rayzebio，Inc.董事会成员，并与他人共同创立了RayzeBio，Inc.，目前是Petrichor附属公司Scion Life Sciences的联合创始人和管理合伙人。从2020年5月至2021年9月，Kantoff先生担任Medicxi的风险合伙人，这是一家专注于生命科学领域的投资公司，他在2021年1月至2022年7月期间担任Centessa制药公司的董事会成员。从2011年8月到2019年4月，坎托夫在生物技术风险投资公司Apple Tree Partners担任合伙人。在ATP任职期间，Kantoff先生担任Syntimmune，Inc.（被Alexion收购）、Corvidia Therapeutics，Inc.（被诺和诺德收购）、Akero Therapeutics, Inc.以及其他私有和上市生物技术公司的董事会成员。在加入ATP之前，坎托夫曾在私人股本和投资银行部门任职。Kantoff先生目前是Tourmaline Bio的董事会成员，这是一家专注于自身免疫性疾病的私营生物技术公司。Kantoff先生在纽约大学Leonard N. Stern商学院获得金融和国际商务学士学位。
- Aaron Kantoff has served on Board since March 2024. Since January 2022, Mr. Kantoff is co founder and managing partner of Scion Life Sciences Management, LLC, which is affiliated with Petrichor Healthcare Capital Management LP. Most recently, beten April 2022 to November 2025, he has served on the board of directors of Tmaline Bio, Inc. (Nasdaq: TRML), a biotechnology company foced on autoimmune diseases. Mr. Kantoff was a co founder and board director of RayzeBio, Inc. (Nasdaq: RYZB) from April 2020 until January 2024. Previoly, he was a venture partner at Medicxi Ventures (UK) LLP ("Medicxi"), an investment firm foced on the life sciences sector. During his time as venture partner at Medicxi, he served on the board of directors of Centessa Pharmaceuticals plc (Nasdaq: CNTA) from November 2020 to July 2022. From August 2011 until April 2019, Mr. Kantoff served as a partner at Apple Tree Partners ("ATP"), a biotechnology venture capital firm. During his time at ATP, Mr. Kantoff was a board member of Syntimmune, Inc. (acquired by Alexion Pharmaceuticals, Inc. (formerly Nasdaq: PALXN), which was subsequently subject to a tender offer by a third party), Corvidia Therapeutics, Inc. (acquired by Novo Nordisk A/S (NYSE: NVO)), Akero Therapeutics, Inc. (previoly Nasdaq: AKRO), as ll as other privately held and publicly traded biotechnology companies. Prior to joining ATP, Mr. Kantoff held roles in private equity and investment banking. Mr. Kantoff received a B.S. in finance and international biness from the New York University Leonard N. Stern School of Biness.
- Maha Katabi
-
Maha Katabi，自2022年8月起担任Rayzebio，Inc.董事会成员。Katabi博士于2019年4月作为合伙人加入生物技术投资公司Sofinnova Investments，自2020年3月起担任普通合伙人。此前，卡塔比博士曾于2018年8月至2019年4月担任风险投资公司Oxalis Capital的创始管理合伙人。从2008年9月到2018年1月，卡塔比博士在Sectoral Asset Management担任投资经理，后来成为私人股本合伙人。Sectoral Asset Management是一家专注于全球医疗保健领域的投资顾问，她是投资于小型和私人生物技术公司的一系列基金的投资组合经理。在加入Sectoral之前，Katabi博士从2004年到2008年在Ventures West担任副总裁，在那里她专注于生命科学行业的早期风险投资。1999年，她在专注于大学初创企业的种子基金T2C2 Capital Bio开始了她的风险投资生涯。卡塔比博士从2021年3月起担任Gyroscope Therapeutics的董事会成员，直到2022年2月被诺华收购；从2020年5月起担任Amplyx Pharmaceuticals的董事会成员，直到2021年4月被辉瑞收购。Katabi博士目前是Aerovate Therapeutics, Inc.、Quanta Therapeutics公司、Sofinnova Investments公司和Vera Therapeutics公司的董事会成员。Aerovate Therapeutics公司是一家上市的临床阶段生物制药公司。她是Exactis Innovation的董事会主席，Exactis Innovation是一家非营利的泛加拿大精准肿瘤研究网络，也是Yale Ventures旗下AmplifyHERscience的顾问。Katabi博士在麦吉尔大学获得药理学博士学位和生物学学士学位，并于2011年获得CFA证书。
Maha Katabi,has served as a member of Board since October 2020. Dr. Katabi joined Sofinnova Investments, a venture capital firm, in April 2019 as a Partner and has been a General Partner since March 2020. Previously, Dr. Katabi was a founding Managing Partner at Oxalis Capital, a venture capital firm, from August 2018 until April 2019. From September 2008 until January 2018, Dr. Katabi was an Investment Manager and later Partner, Private Equity at Sectoral Asset Management, an investment advisor exclusively focused on the global healthcare sector, where she was the portfolio manager of a family of funds investing in small cap and private biotech companies. Prior to joining Sectoral, Dr. Katabi was a Vice President at Ventures West, a venture capital firm, from 2004 to 2008, where she focused on early-stage venture investments in the life sciences industry. She started her venture capital career in 1999 with T2C2 Capital Bio, a seed fund focused on university start-ups. Dr. Katabi was a member of the board of directors of Gyroscope Therapeutics Limited, a gene therapy company, from March 2021 until it was acquired by Novartis AG ("Novartis") in February 2022, and a member of the board of directors of Amplyx Pharmaceuticals, Inc., biopharmaceutical company, from May 2020 until it was acquired by Pfizer Inc. (NYSE: PFE) ("Pfizer") in April 2021, Aiolos Bio, Inc., a biopharmaceutical company, from September 2023 until it was acquired in February 2024 by GSK plc ("GSK"), Aerovate Therapeutics Inc. (Nasdaq: AVTE), a biotechnology company from August 2020 to September 2024, Rayze Bio, Inc. (Nasdaq: RYZB), a biotechnology company, from August 2022 until it was acquired in February 2024 by Bristol Meyers Squibb, and Northsea Therapeutics, B.V. from March 2019 to June 2021. Dr. Katabi currently serves as a member of the board of directors of Quanta Therapeutics, Inc., a biotechnology company, since June 2021, Star Therapeutics, Inc., since June 2023 and Sofinnova Investments. She serves as Chairman of the board of directors of Exactis Innovation, a not-for-profit pan-Canadian research network for precision oncology, and an advisor to amplifyHERscience, a Yale Ventures program dedicated to supporting and promoting science and entrepreneurial pursuits. Dr. Katabi received a Ph.D. in Pharmacology and a B.Sc. in Biology at McGill University and her CFA charter in 2011. - Maha Katabi，自2022年8月起担任Rayzebio，Inc.董事会成员。Katabi博士于2019年4月作为合伙人加入生物技术投资公司Sofinnova Investments，自2020年3月起担任普通合伙人。此前，卡塔比博士曾于2018年8月至2019年4月担任风险投资公司Oxalis Capital的创始管理合伙人。从2008年9月到2018年1月，卡塔比博士在Sectoral Asset Management担任投资经理，后来成为私人股本合伙人。Sectoral Asset Management是一家专注于全球医疗保健领域的投资顾问，她是投资于小型和私人生物技术公司的一系列基金的投资组合经理。在加入Sectoral之前，Katabi博士从2004年到2008年在Ventures West担任副总裁，在那里她专注于生命科学行业的早期风险投资。1999年，她在专注于大学初创企业的种子基金T2C2 Capital Bio开始了她的风险投资生涯。卡塔比博士从2021年3月起担任Gyroscope Therapeutics的董事会成员，直到2022年2月被诺华收购；从2020年5月起担任Amplyx Pharmaceuticals的董事会成员，直到2021年4月被辉瑞收购。Katabi博士目前是Aerovate Therapeutics, Inc.、Quanta Therapeutics公司、Sofinnova Investments公司和Vera Therapeutics公司的董事会成员。Aerovate Therapeutics公司是一家上市的临床阶段生物制药公司。她是Exactis Innovation的董事会主席，Exactis Innovation是一家非营利的泛加拿大精准肿瘤研究网络，也是Yale Ventures旗下AmplifyHERscience的顾问。Katabi博士在麦吉尔大学获得药理学博士学位和生物学学士学位，并于2011年获得CFA证书。
- Maha Katabi,has served as a member of Board since October 2020. Dr. Katabi joined Sofinnova Investments, a venture capital firm, in April 2019 as a Partner and has been a General Partner since March 2020. Previously, Dr. Katabi was a founding Managing Partner at Oxalis Capital, a venture capital firm, from August 2018 until April 2019. From September 2008 until January 2018, Dr. Katabi was an Investment Manager and later Partner, Private Equity at Sectoral Asset Management, an investment advisor exclusively focused on the global healthcare sector, where she was the portfolio manager of a family of funds investing in small cap and private biotech companies. Prior to joining Sectoral, Dr. Katabi was a Vice President at Ventures West, a venture capital firm, from 2004 to 2008, where she focused on early-stage venture investments in the life sciences industry. She started her venture capital career in 1999 with T2C2 Capital Bio, a seed fund focused on university start-ups. Dr. Katabi was a member of the board of directors of Gyroscope Therapeutics Limited, a gene therapy company, from March 2021 until it was acquired by Novartis AG ("Novartis") in February 2022, and a member of the board of directors of Amplyx Pharmaceuticals, Inc., biopharmaceutical company, from May 2020 until it was acquired by Pfizer Inc. (NYSE: PFE) ("Pfizer") in April 2021, Aiolos Bio, Inc., a biopharmaceutical company, from September 2023 until it was acquired in February 2024 by GSK plc ("GSK"), Aerovate Therapeutics Inc. (Nasdaq: AVTE), a biotechnology company from August 2020 to September 2024, Rayze Bio, Inc. (Nasdaq: RYZB), a biotechnology company, from August 2022 until it was acquired in February 2024 by Bristol Meyers Squibb, and Northsea Therapeutics, B.V. from March 2019 to June 2021. Dr. Katabi currently serves as a member of the board of directors of Quanta Therapeutics, Inc., a biotechnology company, since June 2021, Star Therapeutics, Inc., since June 2023 and Sofinnova Investments. She serves as Chairman of the board of directors of Exactis Innovation, a not-for-profit pan-Canadian research network for precision oncology, and an advisor to amplifyHERscience, a Yale Ventures program dedicated to supporting and promoting science and entrepreneurial pursuits. Dr. Katabi received a Ph.D. in Pharmacology and a B.Sc. in Biology at McGill University and her CFA charter in 2011.
- Yi Larson
-
Yi Larson，自2021年4月起担任Rayzebio，Inc.董事会成员。拉森女士自2021年5月起担任上市生物制药公司联生生物的首席财务官。她曾于2019年8月至2021年3月在上市生物制药公司Turning Point Therapeutics, Inc.担任执行副总裁兼首席财务官。拉森女士曾在跨国投资银行和金融咨询公司高盛萨克斯有限责任公司工作，从2008年至2019年8月，她在该公司担任过各种职务，最近一次是从2018年1月至2019年8月，担任医疗保健投资银行董事总经理。在任职于高盛萨克斯公司期间，拉森女士就一系列战略财务事项向多家生物制药公司的董事会和管理团队提供咨询，并执行股票发行、债券发行和并购交易。自2021年4月起，拉森女士还担任Olema Pharmaceuticals, Inc.的董事会成员，该公司是一家上市的临床阶段生物制药公司。拉森女士在麻省理工学院获得了电气工程学士学位和电气工程与计算机科学硕士学位。拉森还获得了宾夕法尼亚大学沃顿商学院金融学MBA学位。
Yi Larson,has served as a member of Rayzebio, Inc. board of directors since April 2021. Ms. Larson has served as the chief financial officer of LianBio, a publicly-traded biopharmaceutical company, since May 2021. She previously served as executive vice president and chief financial officer at Turning Point Therapeutics, Inc., a publicly traded biopharmaceutical company, from August 2019 until March 2021. Ms. Larson previously worked at Goldman Sachs & Co. LLC, a multinational investment bank and financial consulting company, where she held various roles from 2008 until August 2019, most recently as managing director of Healthcare Investment Banking from January 2018 until August 2019. During her tenure at Goldman Sachs & Co. LLC, Ms. Larson advised a variety of biopharmaceutical company boards of directors and management teams on a range of strategic financial matters and executed equity offerings, debt offerings and M&A transactions. Ms. Larson has also served as a member of the board of directors of Olema Pharmaceuticals, Inc., a publicly-traded clinical stage biopharmaceutical company, since April 2021. Ms. Larson received a B.S. in electrical engineering and an M.S. in electrical engineering and computer science, both from the Massachusetts Institute of Technology. Ms. Larson also received an M.B.A. concentrated in finance from the Wharton School at the University of Pennsylvania. - Yi Larson，自2021年4月起担任Rayzebio，Inc.董事会成员。拉森女士自2021年5月起担任上市生物制药公司联生生物的首席财务官。她曾于2019年8月至2021年3月在上市生物制药公司Turning Point Therapeutics, Inc.担任执行副总裁兼首席财务官。拉森女士曾在跨国投资银行和金融咨询公司高盛萨克斯有限责任公司工作，从2008年至2019年8月，她在该公司担任过各种职务，最近一次是从2018年1月至2019年8月，担任医疗保健投资银行董事总经理。在任职于高盛萨克斯公司期间，拉森女士就一系列战略财务事项向多家生物制药公司的董事会和管理团队提供咨询，并执行股票发行、债券发行和并购交易。自2021年4月起，拉森女士还担任Olema Pharmaceuticals, Inc.的董事会成员，该公司是一家上市的临床阶段生物制药公司。拉森女士在麻省理工学院获得了电气工程学士学位和电气工程与计算机科学硕士学位。拉森还获得了宾夕法尼亚大学沃顿商学院金融学MBA学位。
- Yi Larson,has served as a member of Rayzebio, Inc. board of directors since April 2021. Ms. Larson has served as the chief financial officer of LianBio, a publicly-traded biopharmaceutical company, since May 2021. She previously served as executive vice president and chief financial officer at Turning Point Therapeutics, Inc., a publicly traded biopharmaceutical company, from August 2019 until March 2021. Ms. Larson previously worked at Goldman Sachs & Co. LLC, a multinational investment bank and financial consulting company, where she held various roles from 2008 until August 2019, most recently as managing director of Healthcare Investment Banking from January 2018 until August 2019. During her tenure at Goldman Sachs & Co. LLC, Ms. Larson advised a variety of biopharmaceutical company boards of directors and management teams on a range of strategic financial matters and executed equity offerings, debt offerings and M&A transactions. Ms. Larson has also served as a member of the board of directors of Olema Pharmaceuticals, Inc., a publicly-traded clinical stage biopharmaceutical company, since April 2021. Ms. Larson received a B.S. in electrical engineering and an M.S. in electrical engineering and computer science, both from the Massachusetts Institute of Technology. Ms. Larson also received an M.B.A. concentrated in finance from the Wharton School at the University of Pennsylvania.
- Christy Oliger
-
克里斯蒂·奥利格，自2023年8月起担任Rayzebio，Inc.董事会成员。Oliger女士在生物制药行业拥有30多年的经验，从2000年1月至2020年7月退休，在Genentech公司和罗氏控股公司担任过各种商业职务，从1992年9月至1999年12月在Schering-Plough Corporation担任过职务。最近，奥利格女士于2017年1月至2020年7月担任基因泰克公司肿瘤业务部门主管高级副总裁。在基因泰克任职期间，奥利格女士在多个治疗领域担任高级领导职务，包括肿瘤、神经学、罕见病、呼吸学、皮肤学和医院及专科领域的免疫学。她目前是Reata制药公司、Replimune Group、Karyopharm Therapeutics Inc.和Lava Therapeutics的董事会成员，这三家公司都是一家公开上市的制药公司。在此之前，奥利格女士还担任过被GSK收购的Sierra Oncology公司的董事会成员。奥利格获得了加州大学圣巴巴拉分校的经济学学士学位。
Christy Oliger,has served on Rayzebio, Inc. board of directors since August 2023. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, serving in various commercial roles at Genentech, Inc. and Roche Holding AG from January 2000 until her retirement in July 2020, and at Schering-Plough Corporation from September 1992 until December 1999. Most recently, Ms. Oliger served as Senior Vice President, Oncology Business Unit Head, at Genentech, Inc. from January 2017 until July 2020. During her tenure at Genentech, Inc., Ms. Oliger held senior leadership roles across a variety of therapeutic areas, including oncology, neurology, rare diseases, respiratory, dermatology and immunology in hospital and specialty settings. She currently serves as a member of the board of directors of Reata Pharmaceuticals, Inc., Replimune Group Inc., Karyopharm Therapeutics Inc., and Lava Therapeutics, each of which is a publicly-traded pharmaceutical company. Previously, Ms. Oliger also served on the board of Sierra Oncology, Inc. which was acquired by GSK. Ms. Oliger received a B.A. in Economics from the University of California at Santa Barbara. - 克里斯蒂·奥利格，自2023年8月起担任Rayzebio，Inc.董事会成员。Oliger女士在生物制药行业拥有30多年的经验，从2000年1月至2020年7月退休，在Genentech公司和罗氏控股公司担任过各种商业职务，从1992年9月至1999年12月在Schering-Plough Corporation担任过职务。最近，奥利格女士于2017年1月至2020年7月担任基因泰克公司肿瘤业务部门主管高级副总裁。在基因泰克任职期间，奥利格女士在多个治疗领域担任高级领导职务，包括肿瘤、神经学、罕见病、呼吸学、皮肤学和医院及专科领域的免疫学。她目前是Reata制药公司、Replimune Group、Karyopharm Therapeutics Inc.和Lava Therapeutics的董事会成员，这三家公司都是一家公开上市的制药公司。在此之前，奥利格女士还担任过被GSK收购的Sierra Oncology公司的董事会成员。奥利格获得了加州大学圣巴巴拉分校的经济学学士学位。
- Christy Oliger,has served on Rayzebio, Inc. board of directors since August 2023. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, serving in various commercial roles at Genentech, Inc. and Roche Holding AG from January 2000 until her retirement in July 2020, and at Schering-Plough Corporation from September 1992 until December 1999. Most recently, Ms. Oliger served as Senior Vice President, Oncology Business Unit Head, at Genentech, Inc. from January 2017 until July 2020. During her tenure at Genentech, Inc., Ms. Oliger held senior leadership roles across a variety of therapeutic areas, including oncology, neurology, rare diseases, respiratory, dermatology and immunology in hospital and specialty settings. She currently serves as a member of the board of directors of Reata Pharmaceuticals, Inc., Replimune Group Inc., Karyopharm Therapeutics Inc., and Lava Therapeutics, each of which is a publicly-traded pharmaceutical company. Previously, Ms. Oliger also served on the board of Sierra Oncology, Inc. which was acquired by GSK. Ms. Oliger received a B.A. in Economics from the University of California at Santa Barbara.
- Mary Tagliaferri
-
暂无中文简介
Mary Tagliaferri,has served as a member of Rayzebio, Inc. board of directors since September 2021. Dr. Tagliaferri has served as executive clinical fellow of Nektar Therapeutics, a publicly traded global biopharmaceutical company, since April 2020 where she previously served as chief medical officer from November 2017 until March 2020, senior vice president, clinical development from April 2017 until October 2017, and vice president, clinical development from January 2015 until March 2017. Dr. Tagliaferri is the founding member of Chief, a private network built to drive more women into positions of power and keep them there. Previously, Dr. Tagliaferri served as president and chief medical officer of Bionovo, Inc., which was a publicly traded biotechnology company. BioNovo filed for bankruptcy in October 2012. Dr. Tagliaferri currently serves as the chairperson of the board of directors of Enzo Biochem, a publicly traded molecular diagnostics company. Dr. Tagliaferri received a B.S. from Cornell University, an M.S. in Oriental Medicine from American College of Traditional Chinese Medicines and an M.D. from the University of California, San Francisco. -
暂无中文简介
- Mary Tagliaferri,has served as a member of Rayzebio, Inc. board of directors since September 2021. Dr. Tagliaferri has served as executive clinical fellow of Nektar Therapeutics, a publicly traded global biopharmaceutical company, since April 2020 where she previously served as chief medical officer from November 2017 until March 2020, senior vice president, clinical development from April 2017 until October 2017, and vice president, clinical development from January 2015 until March 2017. Dr. Tagliaferri is the founding member of Chief, a private network built to drive more women into positions of power and keep them there. Previously, Dr. Tagliaferri served as president and chief medical officer of Bionovo, Inc., which was a publicly traded biotechnology company. BioNovo filed for bankruptcy in October 2012. Dr. Tagliaferri currently serves as the chairperson of the board of directors of Enzo Biochem, a publicly traded molecular diagnostics company. Dr. Tagliaferri received a B.S. from Cornell University, an M.S. in Oriental Medicine from American College of Traditional Chinese Medicines and an M.D. from the University of California, San Francisco.
- Angie You
-
Angie You，自2022年3月起担任Rayzebio，Inc.董事会成员。尤博士目前是Architect Therapeutics的首席执行官。游博士自2022年2月起担任私募股权和风险投资公司Frazier Healthcare Partners的高级顾问，自2022年4月起担任研究投资公司Casdin Capital的顾问。游博士曾于2018年12月至2022年1月担任私营免疫肿瘤公司Amunix Pharmaceuticals，Inc.的首席执行官，并于2014年9月至2018年12月担任上市的晚期临床药物开发生物制药公司Sierra Oncology, Inc.的首席业务和战略官、商业主管。自2021年11月起，尤博士还担任ORIC制药公司董事会成员，该公司是一家上市的临床阶段生物制药公司。尤博士在哈佛大学获得化学学士学位，在哈佛大学获得生物化学博士学位。
Angie You,has served as a member of Rayzebio, Inc. board of directors since March 2022. Dr. You is currently the chief executive officer of Architect Therapeutics. Dr. You has served as a senior advisor at Frazier Healthcare Partners, a private equity and venture capital firm, since February 2022 and an advisor at Casdin Capital, a research investment firm, since April 2022. Dr. You previously served as the chief executive officer of Amunix Pharmaceuticals, Inc., a private immune-oncology company, from December 2018 until January 2022, and as the chief business and strategy officer, head of commercial at Sierra Oncology, Inc., a publicly-traded late-stage clinical drug development biopharmaceutical company, from September 2014 until December 2018. Dr. You has also served as a member of the board of directors of ORIC Pharmaceuticals, Inc., a publicly-traded clinical stage biopharmaceutical company, since November 2021. Dr. You received a B.A. in chemistry from Harvard College and a Ph.D. in biochemistry from Harvard University. - Angie You，自2022年3月起担任Rayzebio，Inc.董事会成员。尤博士目前是Architect Therapeutics的首席执行官。游博士自2022年2月起担任私募股权和风险投资公司Frazier Healthcare Partners的高级顾问，自2022年4月起担任研究投资公司Casdin Capital的顾问。游博士曾于2018年12月至2022年1月担任私营免疫肿瘤公司Amunix Pharmaceuticals，Inc.的首席执行官，并于2014年9月至2018年12月担任上市的晚期临床药物开发生物制药公司Sierra Oncology, Inc.的首席业务和战略官、商业主管。自2021年11月起，尤博士还担任ORIC制药公司董事会成员，该公司是一家上市的临床阶段生物制药公司。尤博士在哈佛大学获得化学学士学位，在哈佛大学获得生物化学博士学位。
- Angie You,has served as a member of Rayzebio, Inc. board of directors since March 2022. Dr. You is currently the chief executive officer of Architect Therapeutics. Dr. You has served as a senior advisor at Frazier Healthcare Partners, a private equity and venture capital firm, since February 2022 and an advisor at Casdin Capital, a research investment firm, since April 2022. Dr. You previously served as the chief executive officer of Amunix Pharmaceuticals, Inc., a private immune-oncology company, from December 2018 until January 2022, and as the chief business and strategy officer, head of commercial at Sierra Oncology, Inc., a publicly-traded late-stage clinical drug development biopharmaceutical company, from September 2014 until December 2018. Dr. You has also served as a member of the board of directors of ORIC Pharmaceuticals, Inc., a publicly-traded clinical stage biopharmaceutical company, since November 2021. Dr. You received a B.A. in chemistry from Harvard College and a Ph.D. in biochemistry from Harvard University.
- Ken Song
-
Ken Song，自2020年7月起担任Rayzebio，Inc.总裁兼首席执行官，以及Rayzebio，Inc.董事会成员。宋博士是联合创始人，自2021年4月起担任Ablaze Pharmaceuticals Inc.董事会主席。在此之前，宋博士曾在2016年9月至2020年6月期间担任Metacrine, Inc.的总裁、首席执行官和董事会成员，该公司是一家私营的临床阶段生物制药公司。从2010年4月到2016年4月，宋博士担任私人持股的诊断公司Ariosa Diagnostics的首席执行官，他与他人共同创立了这家公司，该公司后来被罗氏收购。宋博士于2017年4月至2021年9月担任私营生命科学工具公司Omniome，Inc.的董事会执行主席，该公司后来被太平洋生物科学收购。宋博士从2007年到2010年在Venrock担任风险投资家，从2000年到2002年在管理咨询公司麦肯锡公司担任顾问。宋博士在麻省理工学院获得生物学学士学位，在加州大学旧金山分校获得医学博士学位。宋博士在加州大学旧金山分校接受内科训练，在华盛顿大学主修胃肠病学和肝病学，并在弗雷德·哈钦森癌症中心担任科学研究员。
Ken Song,has served as Rayzebio, Inc. President and Chief Executive Officer and a member of Rayzebio, Inc. board of directors since July 2020. Dr. Song is the co-founder and has served as the chairman of the board of directors of Ablaze Pharmaceuticals Inc. since April 2021. Previously, Dr. Song served as president, chief executive officer and as a member of the board of directors of Metacrine, Inc., a privately-held clinical-stage biopharmaceutical company during his tenure, from September 2016 until June 2020. From April 2010 until April 2016, Dr. Song served as chief executive officer of Ariosa Diagnostics, a privately-held diagnostics company that he co-founded, which was subsequently acquired by Roche. Dr. Song served as executive chairman of the board of directors of Omniome, nc., a private life science tools company, from April 2017 until September 2021, which was subsequently acquired by Pacific Biosciences. Dr. Song served as a venture capitalist at Venrock from 2007 until 2010 and a consultant at McKinsey & Company, a management consulting company, from 2000 until 2002. Dr. Song received a B.S. in biology from Massachusetts Institute of Technology and an M.D. from University of California, San Francisco. Dr. Song trained in internal medicine at the University of California, San Francisco, specialized in gastroenterology and hepatology at the University of Washington, and was a scientific research fellow at the Fred Hutchinson Cancer Center. - Ken Song，自2020年7月起担任Rayzebio，Inc.总裁兼首席执行官，以及Rayzebio，Inc.董事会成员。宋博士是联合创始人，自2021年4月起担任Ablaze Pharmaceuticals Inc.董事会主席。在此之前，宋博士曾在2016年9月至2020年6月期间担任Metacrine, Inc.的总裁、首席执行官和董事会成员，该公司是一家私营的临床阶段生物制药公司。从2010年4月到2016年4月，宋博士担任私人持股的诊断公司Ariosa Diagnostics的首席执行官，他与他人共同创立了这家公司，该公司后来被罗氏收购。宋博士于2017年4月至2021年9月担任私营生命科学工具公司Omniome，Inc.的董事会执行主席，该公司后来被太平洋生物科学收购。宋博士从2007年到2010年在Venrock担任风险投资家，从2000年到2002年在管理咨询公司麦肯锡公司担任顾问。宋博士在麻省理工学院获得生物学学士学位，在加州大学旧金山分校获得医学博士学位。宋博士在加州大学旧金山分校接受内科训练，在华盛顿大学主修胃肠病学和肝病学，并在弗雷德·哈钦森癌症中心担任科学研究员。
- Ken Song,has served as Rayzebio, Inc. President and Chief Executive Officer and a member of Rayzebio, Inc. board of directors since July 2020. Dr. Song is the co-founder and has served as the chairman of the board of directors of Ablaze Pharmaceuticals Inc. since April 2021. Previously, Dr. Song served as president, chief executive officer and as a member of the board of directors of Metacrine, Inc., a privately-held clinical-stage biopharmaceutical company during his tenure, from September 2016 until June 2020. From April 2010 until April 2016, Dr. Song served as chief executive officer of Ariosa Diagnostics, a privately-held diagnostics company that he co-founded, which was subsequently acquired by Roche. Dr. Song served as executive chairman of the board of directors of Omniome, nc., a private life science tools company, from April 2017 until September 2021, which was subsequently acquired by Pacific Biosciences. Dr. Song served as a venture capitalist at Venrock from 2007 until 2010 and a consultant at McKinsey & Company, a management consulting company, from 2000 until 2002. Dr. Song received a B.S. in biology from Massachusetts Institute of Technology and an M.D. from University of California, San Francisco. Dr. Song trained in internal medicine at the University of California, San Francisco, specialized in gastroenterology and hepatology at the University of Washington, and was a scientific research fellow at the Fred Hutchinson Cancer Center.
高管简历
中英对照 | 中文 | 英文- Ken Song
Ken Song，自2020年7月起担任Rayzebio，Inc.总裁兼首席执行官，以及Rayzebio，Inc.董事会成员。宋博士是联合创始人，自2021年4月起担任Ablaze Pharmaceuticals Inc.董事会主席。在此之前，宋博士曾在2016年9月至2020年6月期间担任Metacrine, Inc.的总裁、首席执行官和董事会成员，该公司是一家私营的临床阶段生物制药公司。从2010年4月到2016年4月，宋博士担任私人持股的诊断公司Ariosa Diagnostics的首席执行官，他与他人共同创立了这家公司，该公司后来被罗氏收购。宋博士于2017年4月至2021年9月担任私营生命科学工具公司Omniome，Inc.的董事会执行主席，该公司后来被太平洋生物科学收购。宋博士从2007年到2010年在Venrock担任风险投资家，从2000年到2002年在管理咨询公司麦肯锡公司担任顾问。宋博士在麻省理工学院获得生物学学士学位，在加州大学旧金山分校获得医学博士学位。宋博士在加州大学旧金山分校接受内科训练，在华盛顿大学主修胃肠病学和肝病学，并在弗雷德·哈钦森癌症中心担任科学研究员。
Ken Song,has served as Rayzebio, Inc. President and Chief Executive Officer and a member of Rayzebio, Inc. board of directors since July 2020. Dr. Song is the co-founder and has served as the chairman of the board of directors of Ablaze Pharmaceuticals Inc. since April 2021. Previously, Dr. Song served as president, chief executive officer and as a member of the board of directors of Metacrine, Inc., a privately-held clinical-stage biopharmaceutical company during his tenure, from September 2016 until June 2020. From April 2010 until April 2016, Dr. Song served as chief executive officer of Ariosa Diagnostics, a privately-held diagnostics company that he co-founded, which was subsequently acquired by Roche. Dr. Song served as executive chairman of the board of directors of Omniome, Inc., a private life science tools company, from April 2017 until September 2021, which was subsequently acquired by Pacific Biosciences. Dr. Song served as a venture capitalist at Venrock from 2007 until 2010 and a consultant at McKinsey & Company, a management consulting company, from 2000 until 2002. Dr. Song received a B.S. in biology from Massachusetts Institute of Technology and an M.D. from University of California, San Francisco. Dr. Song trained in internal medicine at the University of California, San Francisco, specialized in gastroenterology and hepatology at the University of Washington, and was a scientific research fellow at the Fred Hutchinson Cancer Center.- Ken Song，自2020年7月起担任Rayzebio，Inc.总裁兼首席执行官，以及Rayzebio，Inc.董事会成员。宋博士是联合创始人，自2021年4月起担任Ablaze Pharmaceuticals Inc.董事会主席。在此之前，宋博士曾在2016年9月至2020年6月期间担任Metacrine, Inc.的总裁、首席执行官和董事会成员，该公司是一家私营的临床阶段生物制药公司。从2010年4月到2016年4月，宋博士担任私人持股的诊断公司Ariosa Diagnostics的首席执行官，他与他人共同创立了这家公司，该公司后来被罗氏收购。宋博士于2017年4月至2021年9月担任私营生命科学工具公司Omniome，Inc.的董事会执行主席，该公司后来被太平洋生物科学收购。宋博士从2007年到2010年在Venrock担任风险投资家，从2000年到2002年在管理咨询公司麦肯锡公司担任顾问。宋博士在麻省理工学院获得生物学学士学位，在加州大学旧金山分校获得医学博士学位。宋博士在加州大学旧金山分校接受内科训练，在华盛顿大学主修胃肠病学和肝病学，并在弗雷德·哈钦森癌症中心担任科学研究员。
- Ken Song,has served as Rayzebio, Inc. President and Chief Executive Officer and a member of Rayzebio, Inc. board of directors since July 2020. Dr. Song is the co-founder and has served as the chairman of the board of directors of Ablaze Pharmaceuticals Inc. since April 2021. Previously, Dr. Song served as president, chief executive officer and as a member of the board of directors of Metacrine, Inc., a privately-held clinical-stage biopharmaceutical company during his tenure, from September 2016 until June 2020. From April 2010 until April 2016, Dr. Song served as chief executive officer of Ariosa Diagnostics, a privately-held diagnostics company that he co-founded, which was subsequently acquired by Roche. Dr. Song served as executive chairman of the board of directors of Omniome, Inc., a private life science tools company, from April 2017 until September 2021, which was subsequently acquired by Pacific Biosciences. Dr. Song served as a venture capitalist at Venrock from 2007 until 2010 and a consultant at McKinsey & Company, a management consulting company, from 2000 until 2002. Dr. Song received a B.S. in biology from Massachusetts Institute of Technology and an M.D. from University of California, San Francisco. Dr. Song trained in internal medicine at the University of California, San Francisco, specialized in gastroenterology and hepatology at the University of Washington, and was a scientific research fellow at the Fred Hutchinson Cancer Center.
- Arvind Kush
Arvind Kush，自2021年11月起担任Rayzebio公司首席财务官。此前，库什曾于2018年2月至2021年11月担任美银证券全球企业投资银行部医疗集团董事总经理，就战略和融资交易为生物制药公司提供咨询。从2008年7月到2018年1月，库什在美银证券及其前身公司的医疗保健投资银行团队担任越来越多的职务，最近担任董事。2004年1月至2006年6月，库什先生在Caritor India Pvt. Ltd.（现为NTT Data Services）担任高级软件工程师。库什在印度维斯维斯瓦拉亚理工大学获得计算机科学学士学位，在埃默里大学戈伊苏埃塔商学院获得工商管理硕士学位。
Arvind Kush,has served as Rayzebio, Inc. Chief Financial Officer since November 2021. Previously, Mr. Kush served as managing director in the Healthcare Group in the Global Corporate Investment Banking Division at BofA Securities from February 2018 until November 2021, advising biopharmaceutical companies on strategic and financing transactions. From July 2008 until January 2018, Mr. Kush served in roles of increasing responsibilities in the healthcare investment banking team at BofA Securities and its predecessor companies,serving most recently as director. From January 2004 until June 2006, Mr. Kush served as senior software engineer at Caritor India Pvt. Ltd. (now NTT Data Services). Mr. Kush earned a B.E. in computer science from Visvesvaraya Technological University, India, and an M.B.A. from the Goizueta Business School at Emory University.- Arvind Kush，自2021年11月起担任Rayzebio公司首席财务官。此前，库什曾于2018年2月至2021年11月担任美银证券全球企业投资银行部医疗集团董事总经理，就战略和融资交易为生物制药公司提供咨询。从2008年7月到2018年1月，库什在美银证券及其前身公司的医疗保健投资银行团队担任越来越多的职务，最近担任董事。2004年1月至2006年6月，库什先生在Caritor India Pvt. Ltd.（现为NTT Data Services）担任高级软件工程师。库什在印度维斯维斯瓦拉亚理工大学获得计算机科学学士学位，在埃默里大学戈伊苏埃塔商学院获得工商管理硕士学位。
- Arvind Kush,has served as Rayzebio, Inc. Chief Financial Officer since November 2021. Previously, Mr. Kush served as managing director in the Healthcare Group in the Global Corporate Investment Banking Division at BofA Securities from February 2018 until November 2021, advising biopharmaceutical companies on strategic and financing transactions. From July 2008 until January 2018, Mr. Kush served in roles of increasing responsibilities in the healthcare investment banking team at BofA Securities and its predecessor companies,serving most recently as director. From January 2004 until June 2006, Mr. Kush served as senior software engineer at Caritor India Pvt. Ltd. (now NTT Data Services). Mr. Kush earned a B.E. in computer science from Visvesvaraya Technological University, India, and an M.B.A. from the Goizueta Business School at Emory University.
- Susan Moran
Susan Moran，自2021年7月起担任Rayzebio，Inc.首席医疗官。此前，莫兰博士曾于2018年3月至2021年6月担任上市生物技术公司BridgeBio Pharma的附属公司QED治疗公司的首席医疗官。在加入QED之前，莫兰博士于2014年至2018年2月在上市生物制药公司Puma Biotechnology, Inc.工作。莫兰博士一直担任高级医学主任，直到2016年12月，她的职位扩大到副总裁兼临床开发主管。在加入彪马之前，莫兰博士曾于2011年至2014年在上市生物制药公司Takeda Oncology担任医学总监，并于2007年至2011年在上市生物技术公司赛诺菲 Genzyme担任高级医学总监。莫兰博士目前是上市生物制药公司BioAtla，Inc.的董事会成员。莫兰博士是一名获得董事会认证的内科医生，曾在宾夕法尼亚大学医学院和哈佛医学院担任教职。莫兰博士在弗吉尼亚大学获得化学学士学位，在杜克大学获得医学博士学位，在宾夕法尼亚大学医学院获得临床流行病学硕士学位。
Susan Moran has over 20 years of industry and academic experience, successfully leading programs through IND clearance to full regulatory approval. Dr. Moran has served on the board of directors of Tyra Biosciences, Inc. (Nasdaq: TYRA) since May 2024 and Crescent Biopharma since November 2024. From July 2021 to May 2024, Dr. Moran served as Chief Medical Officer of RayzeBio, Inc., a radiopharmaceutical therapeutics company previously listed on Nasdaq that was acquired by Bristol Myers Squibb in February 2024. Prior to joining RayzeBio, Dr. Moran served as Chief Medical Officer at QED Therapeutics, Inc., a biotechnology company and subsidiary of BridgeBio Pharma, Inc. (Nasdaq: BBIO) from March 2018 to June 2021, where she oversaw clinical development of infigratinib, leading to approval of TruseltiqTM. Prior to QED, Dr. Moran was at Puma Biotechnology, Inc. from 2014 to February 2018, contributing to the approval of Nerylnx. She was Senior Medical Director until December 2016 when her role expanded to Vice President and Head of Clinical Development. Dr. Moran has played roles in the development, registration, and post marketing support of products for breast, prostate, thyroid, bile duct, urothelial, lung, and neuroendocrine cancer, as well as multiple sclerosis, achondroplasia, and other disorders. She is a board certified internist and has served on the faculty of the University of Pennsylvania School of Medicine and Harvard Medical School. Dr. Moran received her B.A. from the University of Virginia, M.D. from Duke University, and M.S. in Clinical Epidemiology from the University of Pennsylvania School of Medicine.- Susan Moran，自2021年7月起担任Rayzebio，Inc.首席医疗官。此前，莫兰博士曾于2018年3月至2021年6月担任上市生物技术公司BridgeBio Pharma的附属公司QED治疗公司的首席医疗官。在加入QED之前，莫兰博士于2014年至2018年2月在上市生物制药公司Puma Biotechnology, Inc.工作。莫兰博士一直担任高级医学主任，直到2016年12月，她的职位扩大到副总裁兼临床开发主管。在加入彪马之前，莫兰博士曾于2011年至2014年在上市生物制药公司Takeda Oncology担任医学总监，并于2007年至2011年在上市生物技术公司赛诺菲 Genzyme担任高级医学总监。莫兰博士目前是上市生物制药公司BioAtla，Inc.的董事会成员。莫兰博士是一名获得董事会认证的内科医生，曾在宾夕法尼亚大学医学院和哈佛医学院担任教职。莫兰博士在弗吉尼亚大学获得化学学士学位，在杜克大学获得医学博士学位，在宾夕法尼亚大学医学院获得临床流行病学硕士学位。
- Susan Moran has over 20 years of industry and academic experience, successfully leading programs through IND clearance to full regulatory approval. Dr. Moran has served on the board of directors of Tyra Biosciences, Inc. (Nasdaq: TYRA) since May 2024 and Crescent Biopharma since November 2024. From July 2021 to May 2024, Dr. Moran served as Chief Medical Officer of RayzeBio, Inc., a radiopharmaceutical therapeutics company previously listed on Nasdaq that was acquired by Bristol Myers Squibb in February 2024. Prior to joining RayzeBio, Dr. Moran served as Chief Medical Officer at QED Therapeutics, Inc., a biotechnology company and subsidiary of BridgeBio Pharma, Inc. (Nasdaq: BBIO) from March 2018 to June 2021, where she oversaw clinical development of infigratinib, leading to approval of TruseltiqTM. Prior to QED, Dr. Moran was at Puma Biotechnology, Inc. from 2014 to February 2018, contributing to the approval of Nerylnx. She was Senior Medical Director until December 2016 when her role expanded to Vice President and Head of Clinical Development. Dr. Moran has played roles in the development, registration, and post marketing support of products for breast, prostate, thyroid, bile duct, urothelial, lung, and neuroendocrine cancer, as well as multiple sclerosis, achondroplasia, and other disorders. She is a board certified internist and has served on the faculty of the University of Pennsylvania School of Medicine and Harvard Medical School. Dr. Moran received her B.A. from the University of Virginia, M.D. from Duke University, and M.S. in Clinical Epidemiology from the University of Pennsylvania School of Medicine.